A Phase 2 interventional study of PF-06650833 and PF-06651600 in Rheumatoid Arthritis, sponsored by Pfizer. Completed at 144 sites in 10 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2023-04-07.
Sponsored by Pfizer · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 152 studies in Arthritis, Rheumatoid by Pfizer — 2 open to participants now, 2 under way, none of them phase 3. Arthritis, Rheumatoid · Pfizer.
Among the 152 studies in Arthritis, Rheumatoid by Pfizer, this one is the 19th largest by enrollment of the 86 interventional ones that give a count, is one of 5 that started in 2020, is one of 28 in phase 2, and was the 140th registered.
3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 444 are open to participants now.
Browse Arthritis, Rheumatoid studies →2 of the 152 studies in Arthritis, Rheumatoid by Pfizer are open now, in 1 country. Recruiting first, the newest first:
Pfizer · Sites in Korea, Republic of
Ages 18+
Pfizer
Ages 18–70
By country, each count listing its studies:
Of the 293 Arthritis, Rheumatoid studies recruiting now, 150 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.
This study: 18 Years to 70 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
152 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 24 · Phase 2 29 · Phase 3 18 · Phase 4 17
First in 2003; this study’s year is marked. 5 started in 2020.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 460 is above the median of 95 across 2,221 interventional studies indexed under Arthritis, Rheumatoid.
Median enrollment 155 across the 86 interventional studies, 421 across the 63 observational. Of the 149 that completed or were terminated, 105 (70%) have results posted.
This tab as a report to print or save as PDF → With an account.
Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 152 studies in Arthritis, Rheumatoid by Pfizer, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Dual objectives of increased efficacy compared to currently available SoC RA drugs and maintaining a favourable benefit - risk relationship.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
(ALT) or aspartate aminotransferase (AST) levels ≥1.5 x the (ULN); Participants with a history of Gilbert's syndrome may have a direct measured and would be eligible for this study provided the direct bilirubin is ≤ ULN and other liver function assessments are normal; of \<1.5 x 109/L (\<1500/mm3). Participants with cyclic (benign ethnic) neutropenia will be excluded; Absolute lymphocyte count of \<0.5 x 109/L (\<500/mm3); Absolute white blood cell (WBC) count of \<3.0 x 109/L (\<3000/mm3); \<9.0 g/dL (90 g/L); count ≤100 x 109/L (100,000 cells/mm3) or ≥1000 x 109/L (1,000,000 cells/mm3); Thrombocytopenia, as defined by a platelet count \<100 x 109/L (\<100,000/mm3) at screening visit or within the 3 months prior to first study dose. [Screening laboratory tests with abnormal results may be repeated once to confirm abnormal results. If results return to normal protocol acceptable limits within the 4-week screening period, the participant may enter the study].
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Autoimmune disease
A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.
Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
NYHA class (heart failure)
The New York Heart Association’s four classes of how much heart failure limits physical activity.
Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
GFR and eGFR (kidney filtering)
GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².
Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hemoglobin (Hb)
The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Drug: PF-06650833 · Drug: Tofacitinib
Drug: PF-06650833 · Drug: PF-06651600
Drug: PF-06650833
Drug: PF-06651600
Drug: Tofacitinib
400 mg
100 mg
11 mg
Change From Baseline (BL) in Disease Activity Score (DAS)28-C Reactive Protein (CRP) at Week 12
DAS28 is a measure based on assessment of 28 joints for tenderness and swelling (tender and swollen joint counts). Disease Activity Score 28-C reactive protein (DAS28-CRP) is derived using differential weighting given to 4 components: tender joint count (range: 0-28), swollen joint count (range: 0-28), patient global assessment (recorded on a visual analog scale \[VAS\] scale of 0-100 mm), and CRP (milligram per liter). DAS28-CRP score ranges from 0 to 9.4. The lower the DAS28-CRP score is, the better the participant has response (remission = score\<2.6, low disease activity = score≤3.2). A negative value in change from BL indicates an improvement. Mixed Model Repeated Measures was used for statistical analysis, which used the change from BL of DAS28-CRP as an outcome and treatment, scheduled study visit, BL value of DAS28-CRP, treatment by visit interaction and BL by visit interaction as fixed effects. The model used the unstructured covariance matrix.
Time frame: BL (defined as the last non-missing measurement collected prior to the first administration of study drug on Day 1), Week 12
DAS28-CRP Remission (<2.6) Rates at Week 24
DAS28-CRP is derived using differential weighting given to 4 components: tender joint count, swollen joint count, patient global assessment, and CRP. Remission is defined as DAS28-CRP score \<2.6. Remission rate = the number of responders (who had remission) / (number of responders + non-responders + non-responder assigned by non-responder imputation \[NRI\] after removal of missingness due to COVID-19 and missing components at a given visit)
Time frame: Week 24
Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Treatment Emergent Serious Adverse Events (TESAEs), and Withdrawals Due to TEAEs
An adverse event (AE) was any untoward medical occurrence in a patient or clinical study subject, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A serious AE (SAE) was defined as any untoward medical occurrence that, at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent disability/incapacity; was a congenital anomaly/birth defect; or other serious situations such as important medical events. TEAEs were events between first dose of study drug and up to follow-up visit that were absent before treatment or that worsened after treatment. AEs presented below were TEAEs. The investigator was required to use clinical judgment to assess the potential relationship between investigational product and each AE, to define an treatment-related AE.
Time frame: From first dose of study intervention (Day 1) to Week 28
Number of Participants With Clinical Laboratory Abnormalities (Hematology and Chemistry, Without Regard to Baseline Abnormality)
Clinical laboratory abnormality was determined at the investigator's discretion.
Time frame: From BL to Week 28
Number of Participants With Change From Baseline in Vital Signs Data Meeting the Pre-defined Categorical Summarization Criteria
Abnormality in change from BL in vital signs included: sitting/semi-supine diastolic blood pressure (BP) increase and decrease from BL of \>=20mmHg, systolic BP increase and decrease from BL of \>=30mmHg
Time frame: From BL to Week 28
Number of Participants With Adverse Events of Special Interest
These AEs included severe and opportunistic infection AEs; herpes virus infection AEs; clinically significant categorical increases in hepatic enzymes AST, and ALT and total bilirubin, and potential cases meeting Hy's Law criteria for increased risk of drug induced liver injury (DILI); major adverse cardiovascular events, including pulmonary embolism and deep vein thrombosis, cerebrovascular accident; AEs for decreased renal function, acute kidney injury, clinically significant increases in serum creatinine (Scr) and decreases in estimated glomerular filtration rate (eGFR). Only participants with AEs mentioned above were reported in the table below.
Time frame: From first dose of study intervention (Day 1) to Week 28
Change From Baseline in DAS28-CRP at Week 24
DAS28 is a measure based on assessment of 28 joints for tenderness and swelling (tender and swollen joint counts). DAS28-CRP is derived using differential weighting given to 4 components: tender joint count (range: 0-28), swollen joint count (range: 0-28), patient global assessment (recorded on a visual analog scale \[VAS\] scale of 0-100 mm), and CRP (milligram per liter). DAS28-CRP score ranges from 0 to 9.4. The lower the DAS28-CRP score is, the better the participant has response (remission = score\<2.6, low disease activity = score≤3.2). A negative value in change from BL indicates an improvement.
Time frame: BL (defined as the last non-missing measurement collected prior to the first administration of study drug on Day 1), Week 24
American College of Rheumatology (ACR)20, ACR 50, ACR 70, and ACR 90 Responder Rates at Week 12 and Week 24
The American College of Rheumatology's definition for calculating improvement in rheumatoid arthritis (ACR20) is calculated as a \>=20% improvement in tender and swollen joint counts and 20% improvement in 3 of the 5 remaining ACR core set measures: patient and physician global assessments, pain, disability, and CRP. Similarly, ACR50, ACR70, and ACR 90 were calculated with the respective percent improvement. Responder rate = number of responders (who had ACR20/50/70/90 response)/(number of responders + non-responders + non-responder assigned by non-responder imputation \[NRI\] after removal of missingness due to COVID-19 and missing components at a given visit)
Time frame: BL (defined as the last non-missing measurement collected prior to the first administration of study drug on Day 1), Week 12, Week 24
Change From Baseline in the Tender/Painful and Swollen Joint Count at Week 12 and Week 24
The endpoint included Tender/Painful Joint Count 68 (TJC68) and 28 (TJC28). TJC68 was assessed by a blinded joint assessor to determine the number of joints that were considered tender or painful in upper body and upper/lower extremity. The response to pressure/motion on each joint was assessed using the following scale: Present/Absent/Not Done/Not Applicable (to be used for artificial or missing joints). The 28-joints set is the subset of 68 joints set including the following joints: shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints, and knees. TJC28 was calculated by Pfizer from TJC68. Higher scores indicate higher level of disability.
Time frame: BL (defined as the last non-missing measurement collected prior to the first administration of study drug on Day 1), Week 12, Week 24
Change From Baseline in the Physician's Global Assessment (PhGA) of Arthritis at Week 12 and Week 24
PhGA of Arthritis is an evaluation done by investigator based on the participant's disease signs, functional capacity and physical examination, and should be independent of the Patient's Global Assessment of Arthritis. The investigator's response was recorded using a 100 mm VAS. Physician's Global Assessment score ranges from 0 to 100. Higher scores indicate higher level of disability. A negative value in change from BL indicates an improvement.
Time frame: BL (defined as the last non-missing measurement collected prior to the first administration of study drug on Day 1), Week 12, Week 24
| Milestone | Tofacitinib 11mg MR | PF-06651600 100mg | PF-06650833 400mg MR | PF-06650833 400mg MR + Tofacitinib 11mg MR | PF-06650833 400mg MR + PF-06651600 100mg |
|---|---|---|---|---|---|
| Started | 102 | 77 | 77 | 103 | 101 |
| Completed | 95 | 71 | 73 | 95 | 96 |
| Not completed | 7 | 6 | 4 | 8 | 5 |
| Withdrew: Refused to come for fu visit and was contacted by phone | 0 | 0 | 0 | 1 | 0 |
| Withdrew: Protocol violation | 0 | 1 | 0 | 0 | 1 |
| Withdrew: Lack of efficacy | 2 | 0 | 2 | 1 | 0 |
| Withdrew: Withdrawal by subject | 3 | 4 | 2 | 5 | 3 |
| Withdrew: Death | 1 | 0 | 0 | 0 | 0 |
| Withdrew: Adverse event | 1 | 0 | 0 | 1 | 1 |
| Withdrew: Covid-19 | 0 | 1 | 0 | 0 | 0 |
DAS28 is a measure based on assessment of 28 joints for tenderness and swelling (tender and swollen joint counts). Disease Activity Score 28-C reactive protein (DAS28-CRP) is derived using differential weighting given to 4 components: tender joint count (range: 0-28), swollen joint count (range: 0-28), patient global assessment (recorded on a visual analog scale \[VAS\] scale of 0-100 mm), and CRP (milligram per liter). DAS28-CRP score ranges from 0 to 9.4. The lower the DAS28-CRP score is, the better the participant has response (remission = score\<2.6, low disease activity = score≤3.2). A negative value in change from BL indicates an improvement. Mixed Model Repeated Measures was used for statistical analysis, which used the change from BL of DAS28-CRP as an outcome and treatment, scheduled study visit, BL value of DAS28-CRP, treatment by visit interaction and BL by visit interaction as fixed effects. The model used the unstructured covariance matrix.
| Units on a scale | PF-06650833 400mg MR + Tofacitinib 11mg MR | PF-06650833 400mg MR + PF-06651600 100mg | Tofacitinib 11mg MR | PF-06651600 100mg | PF-06650833 400mg MR |
|---|---|---|---|---|---|
| Change From Baseline (BL) in Disease Activity Score (DAS)28-C Reactive Protein (CRP) at Week 12 | -2.65 (-2.84 to -2.46) | -2.35 (-2.54 to -2.15) | -2.30 (-2.49 to -2.11) | -2.20 (-2.43 to -1.98) | -1.82 (-2.04 to -1.60) |
DAS28-CRP is derived using differential weighting given to 4 components: tender joint count, swollen joint count, patient global assessment, and CRP. Remission is defined as DAS28-CRP score \<2.6. Remission rate = the number of responders (who had remission) / (number of responders + non-responders + non-responder assigned by non-responder imputation \[NRI\] after removal of missingness due to COVID-19 and missing components at a given visit)
| Percentage of participants | PF-06650833 400mg MR + Tofacitinib 11mg MR | PF-06650833 400mg MR + PF-06651600 100mg | Tofacitinib 11mg MR | PF-06651600 100mg | PF-06650833 400mg MR |
|---|---|---|---|---|---|
| DAS28-CRP Remission (<2.6) Rates at Week 24 | 40.8 (32.6 to 48.7) | 31.3 (24.1 to 39.8) | 24.0 (17.1 to 31.8) | 22.4 (14.8 to 31.3) | 11.8 (6.7 to 19.3) |
An adverse event (AE) was any untoward medical occurrence in a patient or clinical study subject, temporally associated with the use of study intervention, whether or not considered related to the study intervention. A serious AE (SAE) was defined as any untoward medical occurrence that, at any dose: resulted in death; was life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; resulted in persistent disability/incapacity; was a congenital anomaly/birth defect; or other serious situations such as important medical events. TEAEs were events between first dose of study drug and up to follow-up visit that were absent before treatment or that worsened after treatment. AEs presented below were TEAEs. The investigator was required to use clinical judgment to assess the potential relationship between investigational product and each AE, to define an treatment-related AE.
| Participants | Tofacitinib 11mg MR | PF-06651600 100mg | PF-06650833 400mg MR | PF-06650833 400mg MR + Tofacitinib 11mg MR | PF-06650833 400mg MR + PF-06651600 100mg |
|---|---|---|---|---|---|
| All-causality TEAEs | 60 | 42 | 38 | 51 | 55 |
| Treatment-related TEAEs | 15 | 17 | 13 | 20 | 25 |
| All-causality TESAEs | 3 | 3 | 3 | 0 | 1 |
| Treatment-related TESAEs | 0 | 0 | 0 | 0 | 0 |
| Discontinuation from study due to all-causality TEAEs | 2 | 0 | 0 | 1 | 1 |
| Discontinuation from study due to treatment-related TEAEs | 1 | 0 | 0 | 1 | 0 |
| Study drug withdrawal due to all-causality TEAEs but continued study | 0 | 6 | 6 | 4 | 6 |
| Study drug withdrawal due to treatment-related TEAEs but continued study | 0 | 4 | 4 | 3 | 4 |
Clinical laboratory abnormality was determined at the investigator's discretion.
| Participants | Tofacitinib 11mg MR | PF-06651600 100mg | PF-06650833 400mg MR | PF-06650833 400mg MR + Tofacitinib 11mg MR | PF-06650833 400mg MR + PF-06651600 100mg |
|---|---|---|---|---|---|
| Hematology: Hemoglobin (gram per deciliter [g/dL]) <0.8x lower limit of normal (LLN) | 2 | 2 | 0 | 2 | 2 |
| Erythrocytes (10^6/millimeter^3 [10^6/mm^3]) <0.8x LLN | 0 | 2 | 0 | 0 | 0 |
| Erythrocyte (Ery.) Mean Corpuscular Volume (micrometer^3 [um^3]) <0.9x LLN | 3 | 2 | 0 | 2 | 0 |
| Ery. Mean Corpuscular Volume (um^3) >1.1x upper limit of normal (ULN) | 4 | 3 | 4 | 3 | 4 |
| Ery. Mean Corpuscular Hemoglobin (picogram/cell [pg/cell]) <0.9x LLN | 8 | 5 | 3 | 7 | 4 |
| Ery. Mean Corpuscular Hemoglobin (HGB) Concentration (g/dL) <0.9x LLN | 8 | 6 | 12 | 10 | 4 |
| Platelets (10^3/mm^3) >1.75xULN | 0 | 0 | 0 | 1 | 0 |
| Reticulocytes/Erythrocytes (%) >1.5x ULN | 2 | 1 | 2 | 1 | 1 |
| Leukocytes (10^3/mm^3) <0.6x LLN | 0 | 1 | 0 | 0 | 1 |
| Leukocytes (10^3/mm^3) >1.5x ULN | 2 | 2 | 1 | 1 | 3 |
| Lymphocytes (10^3/mm^3) <0.8x LLN | 7 | 16 | 3 | 6 | 13 |
| Lymphocytes (10^3/mm^3) >1.2x ULN | 3 | 2 | 1 | 1 | 2 |
| Lymphocytes/Leukocytes (%) <0.8x LLN | 6 | 11 | 9 | 6 | 10 |
| Lymphocytes/Leukocytes (%) >1.2x ULN | 1 | 1 | 1 | 5 | 3 |
| Neutrophils (10^3/mm^3) <0.8x LLN | 2 | 2 | 3 | 5 | 4 |
| Neutrophils (10^3/mm^3) >1.2x ULN | 11 | 16 | 8 | 5 | 14 |
| Neutrophils/Leukocytes (%) <0.8x LLN | 1 | 0 | 0 | 2 | 1 |
| Neutrophils/Leukocytes (%) >1.2x ULN | 5 | 9 | 6 | 3 | 7 |
| Basophils (10^3/mm^3) >1.2x ULN | 0 | 0 | 1 | 1 | 0 |
| Eosinophils (10^3/mm^3) >1.2x ULN | 0 | 0 | 3 | 1 | 0 |
| Eosinophils/Leukocytes (%) >1.2x ULN | 1 | 0 | 5 | 4 | 1 |
| Monocytes (10^3/mm^3) >1.2x ULN | 2 | 1 | 1 | 0 | 2 |
| Monocytes/Leukocytes (%) >1.2x ULN | 8 | 12 | 6 | 11 | 17 |
| Activated Partial Thromboplastin Time (second [sec]) >1.1x ULN | 9 | 9 | 9 | 10 | 10 |
| Prothrombin Time (sec) >1.1x ULN | 7 | 6 | 6 | 2 | 9 |
| Erythrocyte Sedimentation Rate (millimeter per hour [mm/hr]) >1.5x ULN | 72 | 59 | 58 | 71 | 63 |
| Clinical Chemistry: Bilirubin (milligram per deciliter [mg/dL]) >1.5x ULN | 2 | 0 | 0 | 0 | 0 |
| Aspartate Aminotransferase (AST) (unit per liter [U/L]) >3.0x ULN | 0 | 0 | 2 | 1 | 0 |
| Alanine Aminotransferase (ALT) (U/L) >3.0x ULN | 0 | 1 | 7 | 2 | 0 |
| Urea Nitrogen (mg/dL) >1.3x ULN | 4 | 1 | 5 | 4 | 2 |
| Creatinine (mg/dL) >1.3x ULN | 0 | 0 | 0 | 1 | 0 |
| Urate (mg/dL) >1.2x ULN | 3 | 2 | 2 | 4 | 1 |
| Cholesterol (mg/dL) >1.3x ULN | 22 | 13 | 10 | 24 | 20 |
| High-Density Lipoprotein (HDL) Cholesterol (mg/dL) <0.8x LLN | 1 | 3 | 1 | 0 | 1 |
| Low-Density Lipoprotein (LDL) Cholesterol (mg/dL) >1.2x ULN | 9 | 5 | 1 | 5 | 8 |
| Sodium (milliequivalent per liter [mEq/L]) <0.95x LLN | 0 | 1 | 0 | 0 | 0 |
| Potassium (mEq/L) <0.9x LLN | 0 | 1 | 2 | 0 | 1 |
| Potassium (mEq/L) >1.1x ULN | 2 | 3 | 0 | 1 | 1 |
| Chloride (mEq/L) <0.9x LLN | 0 | 1 | 0 | 0 | 0 |
| Calcium (mg/dL) <0.9x LLN | 0 | 0 | 0 | 0 | 1 |
| Bicarbonate (mEq/L) <0.9x LLN | 4 | 2 | 0 | 3 | 2 |
| Creatine Kinase (U/L) >2.0x ULN | 4 | 7 | 1 | 10 | 9 |
| Troponin I (nanogram per milliliter [ng/mL]) >1.0x ULN | 2 | 3 | 2 | 4 | 4 |
| Glucose -FASTING (mg/dL) >1.5x ULN | 3 | 5 | 10 | 10 | 2 |
| Triglycerides -FASTING (mg/dL) >1.3x ULN | 9 | 7 | 4 | 7 | 5 |
| Apolipoprotein A1 (mg/dL) >1.5x ULN | 0 | 1 | 0 | 0 | 0 |
| Apolipoprotein B (mg/dL) >1.5x ULN | 0 | 1 | 0 | 0 | 0 |
Abnormality in change from BL in vital signs included: sitting/semi-supine diastolic blood pressure (BP) increase and decrease from BL of \>=20mmHg, systolic BP increase and decrease from BL of \>=30mmHg
| Participants | Tofacitinib 11mg MR | PF-06651600 100mg | PF-06650833 400mg MR | PF-06650833 400mg MR + Tofacitinib 11mg MR | PF-06650833 400mg MR + PF-06651600 100mg |
|---|---|---|---|---|---|
| Diastolic BP increase >=20mmHg | 1 | 2 | 3 | 6 | 3 |
| Diastolic BP decrease >=20mmHg | 0 | 0 | 0 | 0 | 0 |
| Systolic BP increase >=30mmHg | 1 | 3 | 4 | 2 | 3 |
| Systolic BP decrease >=30mmHg | 0 | 0 | 0 | 0 | 0 |
These AEs included severe and opportunistic infection AEs; herpes virus infection AEs; clinically significant categorical increases in hepatic enzymes AST, and ALT and total bilirubin, and potential cases meeting Hy's Law criteria for increased risk of drug induced liver injury (DILI); major adverse cardiovascular events, including pulmonary embolism and deep vein thrombosis, cerebrovascular accident; AEs for decreased renal function, acute kidney injury, clinically significant increases in serum creatinine (Scr) and decreases in estimated glomerular filtration rate (eGFR). Only participants with AEs mentioned above were reported in the table below.
| Participants | Tofacitinib 11mg MR | PF-06651600 100mg | PF-06650833 400mg MR | PF-06650833 400mg MR + Tofacitinib 11mg MR | PF-06650833 400mg MR + PF-06651600 100mg |
|---|---|---|---|---|---|
| Herpes Zoster | 1 | 1 | 0 | 2 | 0 |
| Oral Herpes | 1 | 0 | 0 | 1 | 2 |
| ALT Increased | 0 | 0 | 3 | 2 | 0 |
| AST Increased | 0 | 0 | 2 | 2 | 0 |
| Hyperbilirubinaemia | 1 | 0 | 0 | 0 | 0 |
| Transaminases Increased | 0 | 0 | 1 | 0 | 0 |
| Hepatic Enzyme Increased | 0 | 0 | 1 | 0 | 0 |
| Liver Injury | 0 | 0 | 1 | 0 | 0 |
DAS28 is a measure based on assessment of 28 joints for tenderness and swelling (tender and swollen joint counts). DAS28-CRP is derived using differential weighting given to 4 components: tender joint count (range: 0-28), swollen joint count (range: 0-28), patient global assessment (recorded on a visual analog scale \[VAS\] scale of 0-100 mm), and CRP (milligram per liter). DAS28-CRP score ranges from 0 to 9.4. The lower the DAS28-CRP score is, the better the participant has response (remission = score\<2.6, low disease activity = score≤3.2). A negative value in change from BL indicates an improvement.
| Units on a scale | PF-06650833 400mg MR + Tofacitinib 11mg MR | PF-06650833 400mg MR + PF-06651600 100mg | Tofacitinib 11mg MR | PF-06651600 100mg | PF-06650833 400mg MR |
|---|---|---|---|---|---|
| Change From Baseline in DAS28-CRP at Week 24 | -3.05 (-3.26 to -2.85) | -2.87 (-3.08 to -2.65) | -2.66 (-2.88 to -2.45) | -2.53 (-2.78 to -2.28) | -2.26 (-2.51 to -2.00) |
The American College of Rheumatology's definition for calculating improvement in rheumatoid arthritis (ACR20) is calculated as a \>=20% improvement in tender and swollen joint counts and 20% improvement in 3 of the 5 remaining ACR core set measures: patient and physician global assessments, pain, disability, and CRP. Similarly, ACR50, ACR70, and ACR 90 were calculated with the respective percent improvement. Responder rate = number of responders (who had ACR20/50/70/90 response)/(number of responders + non-responders + non-responder assigned by non-responder imputation \[NRI\] after removal of missingness due to COVID-19 and missing components at a given visit)
| Percentage of participants | PF-06650833 400mg MR + Tofacitinib 11mg MR | PF-06650833 400mg MR + PF-06651600 100mg | Tofacitinib 11mg MR | PF-06651600 100mg | PF-06650833 400mg MR |
|---|---|---|---|---|---|
| ACR20 (Week 12) | 86.41 (79.94 to 91.59) | 79.21 (71.99 to 85.62) | 83.17 (75.94 to 88.98) | 72.73 (63.80 to 80.94) | 75.00 (66.26 to 82.24) |
| ACR50 (Week 12) | 62.75 (54.69 to 70.75) | 54.46 (45.79 to 62.57) | 46.53 (38.04 to 55.19) | 44.16 (34.59 to 54.16) | 38.16 (29.16 to 47.81) |
| ACR70 (Week 12) | 21.36 (15.35 to 28.95) | 25.74 (19.17 to 33.29) | 23.76 (16.96 to 31.42) | 18.18 (11.34 to 26.08) | 10.53 (5.39 to 18.17) |
| ACR90 (Week 12) | 2.91 (1.07 to 6.86) | 3.96 (1.74 to 8.58) | 0.99 (0.10 to 4.12) | 1.30 (0.14 to 5.32) | 1.32 (0.14 to 5.39) |
| ACR20 (Week 24) | 75.73 (68.31 to 82.41) | 70.00 (61.87 to 77.31) | 75.25 (67.64 to 82.11) | 67.53 (57.99 to 76.32) | 55.26 (45.20 to 65.01) |
| ACR50 (Week 24) | 65.05 (57.08 to 72.34) | 65.00 (56.68 to 72.92) | 65.35 (57.14 to 73.21) | 54.55 (44.56 to 63.80) | 43.42 (33.74 to 53.50) |
| ACR70 (Week 24) | 45.63 (37.25 to 54.20) | 44.00 (35.61 to 52.72) | 44.55 (36.60 to 53.22) | 31.17 (22.51 to 40.74) | 27.63 (19.32 to 36.52) |
| ACR90 (Week 24) | 12.62 (8.05 to 19.19) | 18.00 (12.27 to 25.23) | 9.90 (5.58 to 16.09) | 5.19 (2.28 to 11.34) | 1.32 (0.14 to 5.39) |
The endpoint included Tender/Painful Joint Count 68 (TJC68) and 28 (TJC28). TJC68 was assessed by a blinded joint assessor to determine the number of joints that were considered tender or painful in upper body and upper/lower extremity. The response to pressure/motion on each joint was assessed using the following scale: Present/Absent/Not Done/Not Applicable (to be used for artificial or missing joints). The 28-joints set is the subset of 68 joints set including the following joints: shoulders, elbows, wrists, metacarpophalangeal joints, proximal interphalangeal joints, and knees. TJC28 was calculated by Pfizer from TJC68. Higher scores indicate higher level of disability.
| Joints | PF-06650833 400mg MR + Tofacitinib 11mg MR | PF-06650833 400mg MR + PF-06651600 100mg | Tofacitinib 11mg MR | PF-06651600 100mg | PF-06650833 400mg MR |
|---|---|---|---|---|---|
| TJC28 (Week 12) | -9.87 (-10.65 to -9.09) | -9.78 (-10.58 to -8.98) | -9.84 (-10.63 to -9.05) | -9.83 (-10.76 to -8.91) | -8.82 (-9.73 to -7.92) |
| TJC68 (Week 12) | -14.96 (-16.09 to -13.83) | -15.66 (-16.81 to -14.50) | -15.32 (-16.47 to -14.18) | -14.80 (-16.13 to -13.46) | -13.76 (-15.07 to -12.46) |
| SJC28 (Week 12) | -8.61 (-9.16 to -8.06) | -8.16 (-8.73 to -7.60) | -7.86 (-8.41 to -7.30) | -8.30 (-8.95 to -7.65) | -7.80 (-8.44 to -7.15) |
| SJC66 (Week 12) | -11.29 (-11.99 to -10.59) | -10.90 (-11.62 to -10.19) | -10.34 (-11.05 to -9.63) | -10.75 (-11.58 to -9.92) | -10.18 (-11.00 to -9.37) |
| TJC28 (Week 24) | -11.33 (-12.06 to -10.61) | -11.44 (-12.20 to -10.68) | -10.60 (-11.34 to -9.86) | -10.47 (-11.34 to -9.59) | -10.31 (-11.20 to -9.42) |
| TJC68 (Week 24) | -16.68 (-17.78 to -15.57) | -17.68 (-18.82 to -16.53) | -16.76 (-17.88 to -15.64) | -16.69 (-18.02 to -15.36) | -15.79 (-17.13 to -14.46) |
| SJC28 (Week 24) | -8.83 (-9.34 to -8.31) | -9.44 (-9.98 to -8.90) | -8.76 (-9.29 to -8.24) | -8.71 (-9.33 to -8.08) | -8.28 (-8.92 to -7.65) |
| SJC66 (Week 24) | -11.41 (-12.02 to -10.80) | -12.38 (-13.03 to -11.74) | -11.59 (-12.21 to -10.97) | -11.45 (-12.19 to -10.71) | -11.10 (-11.86 to -10.34) |
PhGA of Arthritis is an evaluation done by investigator based on the participant's disease signs, functional capacity and physical examination, and should be independent of the Patient's Global Assessment of Arthritis. The investigator's response was recorded using a 100 mm VAS. Physician's Global Assessment score ranges from 0 to 100. Higher scores indicate higher level of disability. A negative value in change from BL indicates an improvement.
| Units on a scale | PF-06650833 400mg MR + Tofacitinib 11mg MR | PF-06650833 400mg MR + PF-06651600 100mg | Tofacitinib 11mg MR | PF-06651600 100mg | PF-06650833 400mg MR |
|---|---|---|---|---|---|
| PhGA of Arthritis (Week 12) | -43.50 (-46.32 to -40.69) | -41.20 (-44.06 to -38.34) | -40.86 (-43.72 to -38.00) | -38.62 (-41.95 to -35.28) | -31.56 (-34.82 to -28.30) |
| PhGA of Arthritis (Week 24) | -47.50 (-50.13 to -44.87) | -48.21 (-50.95 to -45.47) | -47.31 (-49.98 to -44.63) | -43.42 (-46.60 to -40.25) | -39.27 (-42.49 to -36.05) |
Collected over From first dose of study intervention (Day 1) to Week 28. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Tofacitinib 11mg MR | 1/102 (1%) | 3/102 (2.9%) | 24/102 (23.5%) |
| PF-06651600 100mg | 0/77 (0%) | 3/77 (3.9%) | 18/77 (23.4%) |
| PF-06650833 400mg MR | 0/77 (0%) | 3/77 (3.9%) | 11/77 (14.3%) |
| PF-06650833 400mg MR + Tofacitinib 11mg MR | 0/103 (0%) | 0/103 (0%) | 19/103 (18.4%) |
| PF-06650833 400mg MR + PF-06651600 100mg | 0/101 (0%) | 1/101 (1%) | 26/101 (25.7%) |
| Event | Tofacitinib 11mg MR | PF-06651600 100mg | PF-06650833 400mg MR | PF-06650833 400mg MR + Tofacitinib 11mg MR | PF-06650833 400mg MR + PF-06651600 100mg |
|---|---|---|---|---|---|
| Femur fractureInjury, poisoning and procedural complications | 0/102 | 1/77 | 0/77 | 0/103 | 0/101 |
| Diabetic ketoacidosisMetabolism and nutrition disorders | 0/102 | 1/77 | 0/77 | 0/103 | 0/101 |
| Lumbar spinal stenosisMusculoskeletal and connective tissue disorders | 0/102 | 0/77 | 1/77 | 0/103 | 0/101 |
| Uterine leiomyomaNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/102 | 1/77 | 0/77 | 0/103 | 0/101 |
| Renal colicRenal and urinary disorders | 0/102 | 0/77 | 1/77 | 0/103 | 0/101 |
| Endometrial hyperplasiaReproductive system and breast disorders | 0/102 | 0/77 | 1/77 | 0/103 | 0/101 |
| Uterine polypReproductive system and breast disorders | 0/102 | 0/77 | 1/77 | 0/103 | 0/101 |
| COVID-19 pneumoniaInfections and infestations | 0/102 | 0/77 | 0/77 | 0/103 | 1/101 |
| Coronavirus infectionInfections and infestations | 1/102 | 0/77 | 0/77 | 0/103 | 0/101 |
| Skin squamous cell carcinoma recurrentNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 1/102 | 0/77 | 0/77 | 0/103 | 0/101 |
| Event | Tofacitinib 11mg MR | PF-06651600 100mg | PF-06650833 400mg MR | PF-06650833 400mg MR + Tofacitinib 11mg MR | PF-06650833 400mg MR + PF-06651600 100mg |
|---|---|---|---|---|---|
| SARS-CoV-2 test positiveInvestigations | 7/102 | 1/77 | 2/77 | 4/103 | 8/101 |
| HeadacheNervous system disorders | 4/102 | 4/77 | 2/77 | 3/103 | 7/101 |
| Urinary tract infectionInfections and infestations | 5/102 | 1/77 | 1/77 | 7/103 | 3/101 |
| NauseaGastrointestinal disorders | 4/102 | 5/77 | 2/77 | 1/103 | 3/101 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 3/102 | 5/77 | 1/77 | 2/103 | 2/101 |
| NasopharyngitisInfections and infestations | 3/102 | 2/77 | 1/77 | 3/103 | 6/101 |
| Rheumatoid arthritisMusculoskeletal and connective tissue disorders | 3/102 | 4/77 | 4/77 | 1/103 | 1/101 |
Baseline analysis population included all participants randomly assigned to study intervention and who took at least 1 dose of study intervention. Participants were analyzed according to the intervention they actually received.
| Age, Continuous(Years) | Tofacitinib 11mg MR | PF-06651600 100mg | PF-06650833 400mg MR | PF-06650833 400mg MR + Tofacitinib 11mg MR | PF-06650833 400mg MR + PF-06651600 100mg | Total |
|---|---|---|---|---|---|---|
| Mean | 51.2 ± 10.63 | 52.8 ± 10.90 | 53.6 ± 9.87 | 54.0 ± 10.41 | 53.0 ± 10.40 | 52.9 ± 10.46 |
| Age, Customized(Participants) | Tofacitinib 11mg MR | PF-06651600 100mg | PF-06650833 400mg MR | PF-06650833 400mg MR + Tofacitinib 11mg MR | PF-06650833 400mg MR + PF-06651600 100mg | Total |
|---|---|---|---|---|---|---|
| 18-44 | 25 | 17 | 11 | 19 | 21 | 93 |
| 45-64 | 68 | 49 | 56 | 71 | 66 | 310 |
| >=65 | 9 | 11 | 10 | 13 | 14 | 57 |
| Sex: Female, Male(Participants) | Tofacitinib 11mg MR | PF-06651600 100mg | PF-06650833 400mg MR | PF-06650833 400mg MR + Tofacitinib 11mg MR | PF-06650833 400mg MR + PF-06651600 100mg | Total |
|---|---|---|---|---|---|---|
| Female | 82 | 62 | 61 | 78 | 73 | 356 |
| Male | 20 | 15 | 16 | 25 | 28 | 104 |
| Race/Ethnicity, Customized(Participants) | Tofacitinib 11mg MR | PF-06651600 100mg | PF-06650833 400mg MR | PF-06650833 400mg MR + Tofacitinib 11mg MR | PF-06650833 400mg MR + PF-06651600 100mg | Total |
|---|---|---|---|---|---|---|
| White | 101 | 76 | 77 | 102 | 101 | 457 |
| Asian | 1 | 0 | 0 | 0 | 0 | 1 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 1 | 0 | 1 |
| Multiracial | 0 | 1 | 0 | 0 | 0 | 1 |
Showing the first 100 of 144 sites across 10 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Data sharing details ↗ · www.pfizer.com
Ran from Jul 2020 to primary completion in Feb 2022, 18 months.
Results were first posted in Apr 2023, 1 year 2 months after primary completion.
Of 116 industry-sponsored phase 2 interventional studies under Arthritis, Rheumatoid, half reached primary completion within 17 months of starting (the median), counting those still running; a quarter within 13 and three quarters within 24. This study's 18 months is close to that.
Counting every sponsor, half of 158 studies reached it within 18 months; a quarter within 13 and three quarters within 30.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Zimlovisertib · PF-06651600 · Tofacitinib